-
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
•
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration indicated that the influenza virus split vaccine marketing application from Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)’s wholly-owned subsidiary, Zhifei Longkoma, has been accepted, with the acceptance number CXSS2400114. Currently, Chongqing Zhifei Biological has…
-
Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has announced that it has received market approval in Indonesia for its in-house developed Category 1 drug, the recombinant Mycobacterium tuberculosis fusion protein (EC) injection. This development marks an important milestone for the company as it…
-
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released its financial report for 2023, recording revenues of RMB 52.918 billion (USD 7.3 billion), an increase of 38.3% year-on-year (YOY). Net profits for the company were reported at RMB 8.07 billion (USD 1.11 billion), marking…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals
•
In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline (GSK; NYSE: GSK), highlighted China as a key source of innovative molecules for licensing agreements. Miels attributes this trend to China’s robust chemistry capabilities and the willingness of local companies to out-license their rights: “You…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
•
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and co-promotion agreement with UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) for its shingles vaccine, Shingrix (recombinant zoster vaccine; RZV). This partnership marks a significant step in enhancing the availability of Shingrix in the Chinese market.…
